Combination Antibody Therapy Market - High Growth by 2016 - 2022

Combination Antibody Therapy Market - High
Growth by 2016 - 2022

P e r s i s t e n c e M a r k e t R e s e a r c h
About Us
Persistence Market Research (PMR) is a market intelligence company, providing global business information
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking
insight for thousands of decision makers. We have an experienced team of Analysts, Researchers,
and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze
information. Our business offerings represent the latest and the most reliable information indispensable for
businesses to sustain a competitive edge.
Each PMR Syndicated Research report covers a different sector - such as pharmaceuticals, chemical,
energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports
provide in-depth analysis and deep segmentation to possible micro levels. With a wider scope and stratified
research methodology, our syndicated reports strive to serve clients and satisfy their overall research
requirement.
Copyright © 2015 Persistence Market Research
All Rights Reserved. This document contains highly confidential information and is the sole property of PMR.
No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of PMR.
Combination Antibody Therapy Market, 2016 - 2022 Page |

P e r s i s t e n c e M a r k e t R e s e a r c h
Report Media Releases
Combination Antibody Therapy Market - High Growth by 2016 -
2022
Combination antibody therapy has gained significant recognition in past two decades. It is now a preferred drug
treatment for cancers such as lymphomas and solid tumors. Antibodies for modulating immune system has also
achieved a significant success clinically. Combination antibody therapy are crucial strategies for treating patients
suffering from hematological malignancies and solid tumors. This therapy for tumors is based on the fundamentals of
cancer cell’s antigen expression. Combination antibody therapy can function through mediating changes in antigen or
receptor functions or modulating the immune system or administering a drug that becomes temporarily united with the
antibody, for targeting a specific antigen. According to the journal of oncology (JCO) it has been concluded that a
combination of epratuzumab with rituximab was tolerable and had substantial effect in Non-Hodgkin's Lymphoma (NHL).
Nonetheless, auto immune disease such as rheumatoid arthritis can be treated by combination of alpha monoclonal
antibody with low dose weekly of methotrexate. Additive effect of Rituxan anti-CD20 chimeric antibody with low dose
chemotherapy can be effective in B-Cell Lymphoma.
Request to view TOC : http://www.persistencemarketresearch.com/toc/11740
The particular nature of the combination antibody therapy has led to more targeted and specific treatment of the cancer
and tumor. Hence, become an attractive treatment in recent years due to its non-chemotherapy nature, which in turn
gives a safe and secure process of killing the cancer and tumor cells. Growth for combination antibody treatment market
is anticipated to gain traction in near future due to the above mentioned factors. Owing to the ability of combination
antibodies to specifically target tumor cells and cancer cells has been crucial for the advancement of monoclonal
antibodies combination therapy so far due to that it is expected that the CAGR for combination antibody therapy market
is tend to expand in near future. Combination antibody therapy market is anticipated to grow on the backdrop of
increased effort for developing dual targeting of tumor antigens such as bi-specific ADC’s and novel strategies such as
masked antibodies.
Requirement of safe and chemotherapy-free cancer treatments have led towards rise in demand for combination
antibody therapy. Major part of the demand is expected to be under chronic lymphocytic leukemia. However, over the
year significant number of antibodies and immune system modulators have been introduced in various other cancer
treatments, which has shown positive effects of disease disposal. The more convenient way for drug administration has
empowered the growth of these type of cancer treatments, which further offers more patient compliance. Furthermore,
the rise in prevalence of cancer around the globe has been a positive sign for combination antibody therapy market that
in turn is expected to underpin the growth in use of combination therapy.
Global market for Combination antibody therapy is segmented on the basis of disease, basis of drugs, route of
administration and end user:
Segmentation by Disease
o Cancer
o Tumor
o Auto-immune disorder
Segmentation by Drugs
o Nivolumab and Ipilimumab
o Trastuzumab and Pertuzumab
o Rituximab and Apolizumab
o Ofatumumab, and Obinutuzumab
Combination Antibody Therapy Market, 2016 - 2022 Page |

P e r s i s t e n c e M a r k e t R e s e a r c h
o Ipilimumab and Bevacizumab
o Others
Segmentation by Route of administration
o Oral
o Parenteral
Segmentation by End User
o Hospitals
o Ambulatory Surgical Centers
o Cancer institutions
o Clinical research institutes
Primary revenue drivers for combination antibody therapy are an increase in number of patients seeking safe and
chemotherapy free treatment. High rate of cancer in human population globally, is estimated to affect significantly in
combination antibody therapy market worldwide. Other revenue drivers include life style changes and rise in adulterated
food consumption by individuals. Furthermore, the combination antibody therapy market is expected to grow on the
backdrop of rise in cases of skin tumors, which includes basal cell and squamous cell carcinomas and make up 12% of
all skin tumors.
On the basis of region presence, Combination antibody therapy market is segmented into five key regions: North
America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Currently, North America dominates the global
market for Combination antibody therapy due to high adoption and diagnosis rate, followed by Europe. Rising number
of cancer patients is expected to fuel the Combination antibody therapy market. Combination antibody therapy market
in Asia Pacific and Middle East and Africa is expected to register high growth due to developing healthcare infrastructure
and high prevalence of tumor and cancer.
Some of the major market players in Combination antibody therapy market globally include Laboratory Corporation of
EMD Millipore Corporation, Thermo Fisher Scientific Inc., GeneTex Inc., Novus Biologicals, BioLegend, Inc., PDL
BioPharma, Inc, Fortress Biotech., Peregrine Pharmaceuticals Inc., Cellerant Therapeutics, Inc., Aspyrian
Therapeutics, Inc. The report covers exhaustive analysis on:
Combination antibody therapy Market Segments
Combination antibody therapy Market Dynamics
Historical Actual Market Size, 2014 - 2015
Combination antibody therapy Market Size & Forecast 2016 to 2022
Combination antibody therapy Current Trends/Issues/Challenges
Competition & Companies involved
Combination antibody therapy Drivers and Restraints
Request to view Sample Report : http://www.persistencemarketresearch.com/samples/11740
Regional analysis includes
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Report Highlights:
Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Combination Antibody Therapy Market, 2016 - 2022 Page |

P e r s i s t e n c e M a r k e t R e s e a r c h
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance
For information regarding permissions, contact:
Persistence Market Research
90 Sate Street, Suite 700 Albany, NY 12207
Tel: +1-518-618-1030
Email: sales@persistencemarketresearch.com
Website: http://www.persistencemarketresearch.com/
media@persistencemarketresearch.com
Combination Antibody Therapy Market, 2016 - 2022 Page |